A Pilot Study of MK-0752 in Combination With Tamoxifen or Letrozole in Patients With Early Stage Breast Cancer Prior to Surgery
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 May 2018
At a glance
- Drugs MK 0752 (Primary) ; Letrozole; Tamoxifen
- Indications Breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 02 Apr 2015 Planned End Date changed from 1 Jan 2012 to 1 May 2018 as reported by ClinicalTrials.gov record.
- 14 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.